Mahmoud A. Kaimi, MD
Dr. Khaimi is a Clinical Associate Professor at the Dean McGee Eye Institute, University of Oklahoma in Oklahoma City, USA. He completed his ophthalmology residency at Henry Ford Hospital in Detroit, Michigan, before undertaking a fellowship in glaucoma at the Dean McGee Eye Institute. He joined the faculty at the Dean McGee Eye Institute in 2007. His special interests include minimally invasive glaucoma surgery, filtration and glaucoma drainage surgery for glaucoma, complex cataracts.
Dr. Khaimi was one of the first adopters of traditional ab externo Canaloplasty, having performed more than 1000 procedures. More recently, he pioneered ABiC and has completed an 18-month analysis of the procedure’s efficacy in POAG patients, both as a stand-alone procedure, and in conjunction with cataract surgery. Dr. Khaimi was previously the primary investigator for the “Primary Trabeculectomy versus Tube” study, InnFocus study and several pharmaceutical research studies. He has been co-investigator for the Express mini shunt versus Trabeculectomy (XVT) study, the COMPASS study, and the Ologen versus Mitomycin C study.
I have been a practicing glaucoma specialist for over 10 years. The introduction of ABiC has completely changed my glaucoma treatment paradigm. Not only has ABiC proven itself to be highly effective in lowering IOP and reducing medication dependence, it also offers an excellent safety profile. There is no manipulation of the conjunctiva, and the post-op recovery resembles that of cataract surgery.